News

20 years after initiating preventive tamoxifen, less breast cancer but no survival benefit

Publish date: December 15, 2014

 

AT SABCS 2014

References

The tamoxifen-associated risk of any other cancers was nonsignificant.

The IBIS-I trial was supported by Cancer Research UK. Dr. Cuzick has received funding for other trials from AstraZeneca and is a consultant for AstraZeneca. The company also provided both the study drug and placebo.

msullivan@frontlinemedcom.com

On Twitter @alz_gal

Pages

Recommended Reading

Mastectomies, reconstruction, on the rise for women with early stage disease
MDedge ObGyn
Bariatric surgery an opportunity to screen for endometrial cancer
MDedge ObGyn
Breast cancer relapse risk halved since 1986
MDedge ObGyn
Ultrasound screening for dense breasts is high cost, offers little benefit
MDedge ObGyn
Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients
MDedge ObGyn
VIDEO: High TILs associated with less efficacy from trastuzumab
MDedge ObGyn
North America has highest rate of obesity-related cancers
MDedge ObGyn
Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients
MDedge ObGyn
SOFT trial endorses selective ovarian suppression in early breast cancer
MDedge ObGyn
VIDEO: What was the most interesting thing you learned at the meeting?
MDedge ObGyn